Roche Cancer Immunotherapy Tecentriq II Clinical Study IMpassion130 Reaches Major Endpoint

recently, SwissPharmaceuticals(Roche) announced that iMpassion130, a phase III clinical study of the evaluation of the cancer immunotherapy tecentriq (TNBC) first-line chemotherapy treatment, has reached a common major endpoint of progression-free survival (PFS)related research
a multicenter, randomized, double-blind Phase III study, conducted in 902 patients with metastasized or non-rectructive local late TNBC who had not received systematic therapy to treat metastases, evaluated tecentriq combination chemotherapy (Abraxane (albumin-binding yew alcohol, nab-paclitaxel) for first-line therapy, safety and efficacy in combination with the placebo and chemotherapy (Axbraane) programInthe study, patients were randomly assigned to tecentriq-chemotherapy treatment group or placebo-chemotherapy treatment group at a ratio of 1:1The main endpoints of the study were PFS (assessed according to RECIST 1.1) and total lifetime (OS)results showed that tecentriq-chemotherapy (Abraxane) first-line treatment significantly reduced the risk of disease deterioration or death (PFS) in patients with metastatic or non-rectrusised local late TNBC compared to single-use chemotherapy (Abraxane)This mid-termanalysis(when total lifetime (OS) data in PD-L1-positive patients were encouragingPatients in this study will continue to follow up until the next analysissafety
tecentriq and Abraxane combined drug safety is consistent with theof variousdrugs (known safety) and no new safety signals have been found the results of the study will be presented at the upcoming Medical Conference and will be presented to regulators around the world, including the U.S Food and Drug Administration (
FDA
and the European Drug (EMA)